Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02667015 · ClinicalTrials.gov registry record · Phase 2
Development of an Anxiety Sensitivity-Based Intervention for Substance Use and Anxiety Comorbidity
A Phase 2 study, sponsored by Hartford Hospital.
- Completed
- Registry status
- Phase 2
- Development phase
- 41
- Enrollment target
NCT02667015: Completed Phase 2 study, sponsored by Hartford Hospital.
NCT02667015 is a Phase 2 study that has completed, run by Hartford Hospital. The registered enrollment target is 41 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (69% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02667015, a Phase 2 study, has completed, sponsored by Hartford Hospital.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 41 participants
- Enrollment target
Study Summary
The aim of the current study is to develop and pilot test an anxiety sensitivity-based intervention for co-occurring substance use disorders (SUDs) and anxiety. Research questions include determining whether a broadly-applicable AS-based intervention can significantly decrease both substance misuse and anxiety. Secondary aims include examining the impact of this intervention on general functioning and depressive/anxious symptoms. In phase I, an initial pilot was conducted to examine the feasibility, safety, and patient satisfaction with the protocol, and to estimate potential efficacy of the protocol. In phase II, participants will be randomized to the intervention or a control condition.
Primary Outcome
The ASI is a self-report measure consisting of 16 questions which ask about past-week fear of physical and psychological symptoms of anxiety and fear of potential sequelae of anxiety (e.g., "When I notice my heart is beating rapidly, I worry that might have a heart attack"; or "When my stomach is upset, I worry I might be seriously ill"). Scores over 25 are suggestive of clinically significant anxiety sensitivity (Peterson \& Plehn, 1999).
Interventions
- BEHAVIORAL Psychotherapy (Anxiety Sensitivity Intervention)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 41 participants |
| Start Date | 2012-05 |
| Est. Completion | 2015-05 |
| Phase | Phase 2 |
What the finished NCT02667015 record still lists
NCT02667015 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 41 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (69% lower).
The record links to 0 conditions, and to 1 intervention - of which Psychotherapy (Anxiety Sensitivity Intervention) is the first listed.
NCT02667015 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02667015 about?
NCT02667015 is a clinical study titled "Development of an Anxiety Sensitivity-Based Intervention for Substance Use and Anxiety Comorbidity". The aim of the current study is to develop and pilot test an anxiety sensitivity-based intervention for co-occurring substance use disorders (SUDs) and anxiety. Research questions include determining whether a broadly-applicable AS-based intervention can significantly decrease both substance misuse ...
What is the current status of trial NCT02667015?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 41 participants. The study started on 2012-05. Estimated completion is 2015-05.
What interventions are being tested in trial NCT02667015?
The interventions under investigation include: Psychotherapy (Anxiety Sensitivity Intervention) (BEHAVIORAL).
Who is sponsoring clinical trial NCT02667015?
This trial is sponsored by Hartford Hospital, which has 75 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02667015's enrollment target sits among peer trials
41 1352nd of 2000 higher than 639 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03449238 · 41 participants · Phase 1
Pembrolizumab And Stereotactic Radiosurgery (Srs) Of Selected Brain Metastases In Breast Cancer Patients
- NCT03900793 · 41 participants · Phase 1
Losartan + Sunitinib in Treatment of Osteosarcoma
- NCT04082520 · 41 participants · Phase 2
Lutathera for the Treatment of Inoperable, Progressive Meningioma After External Beam Radiation Therapy
- NCT04220190 · 41 participants · Phase 2
RAPA-501 Therapy for ALS
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia